On February 1, 2022 Bio-Techne Corporation (NASDAQ: TECH) reported that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended December 31, 2021 (Press release, Bio-Techne, FEB 1, 2022, View Source [SID1234607580]). The quarterly dividend will be payable February 25, 2022, to all common shareholders of record on February 11, 2022. Future cash dividends will be considered by the Board of Directors on a quarterly basis.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Bio-Techne also announced today that its board of directors has approved a new share repurchase program authorizing the repurchase of up to $400 million of common stock. The new share repurchase program begins February 2, 2022 and replaces the previous program. The timing and number of shares to be repurchased will depend on factors such as the share price, economic and market conditions, and corporate and regulatory requirements. The share repurchase program may be suspended, amended, or discontinued at any time and does not obligate the Company to acquire any specific dollar amount or number of shares of common stock.

On February 1, 2022 Orion Corporation reported that 38,220 A shares have been converted into 38,220 B shares (Press release, Orion , FEB 1, 2022, View Source,Register%20on%201%20February%202022. [SID1234607579]). The conversion has been entered into the Trade Register on 1 February 2022 .

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The total number of shares in Orion Corporation is 141,134,278 which, after the conversion, consists of 34,774,986 A shares and 106,359,292 B shares. The number of votes of the company’s shares is after the conversion 801,859,012.

On February 1, 2022 SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, reported that management will present at the following upcoming investor conferences (Press release, SpringWorks Therapeutics, FEB 1, 2022, View Source [SID1234607577]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

2022 Guggenheim Oncology Conference on Thursday, February 10 from 10:00-10:25 am ET.
Cowen 42nd Annual Health Care Conference on Monday, March 7 from 1:30-2:00 pm ET.
Barclays Global Healthcare Conference on Wednesday, March 16 from 9:30-10:00 am ET.
Webcasts of these events will be available on the Events & Presentations page within the Investors & Media section of the company’s website at View Source Replays of the webcasts will be available on SpringWorks’ website for a limited time following each conference.

On February 1, 2022 Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, reported an update on the Phase III clinical trial, FLAMINGO-01 (Press release, Greenwich LifeSciences, FEB 1, 2022, View Source [SID1234607576]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company has made significant progress towards study initiation:

– Contract Research Organization (CRO) has been contracted for study start-up, project management, data management, and clinical data monitoring

– Manufacturing of third clinical lot of GP2 using a commercial line has been completed

– Commercial lots of GP2 active ingredient for filing of BLA have been contracted

– Central Laboratory has been contracted for screening of HLA type

– Drug and biological sample storage sites and other study infrastructure have been put in place

– Central Institutional Review Board (IRB) approval has been granted for the study

– Clinical trial sites continue in the study start-up process and the Company continues to solicit additional US and international sites and networks for participation in the study

About FLAMINGO-01 and GLSI-100

The Phase III clinical trial will be called FLAMINGO-01 and the combination of GP2 + GM-CSF will be called GLSI-100. The Phase III trial is comprised of 2 blinded, randomized, placebo-controlled arms for approximately 500 HLA-A*02 patients and 1 open label arm of up to 100 patients for all other HLA types. An interim analysis has been designed to detect a hazard ratio of 0.3 in IDFS, where 28 events will be required. An interim analysis for superiority and futility will be conducted when at least half of those events, 14, have occurred. This sample size provides 80% power if the annual rate of events in placebo-treated subjects is 2.4% or greater. The trial is currently being registered on clinicaltrials.gov. For future updates about FLAMINGO-01 please visit the Company’s clinical trial tab at View Source

About Breast Cancer and HER2/neu Positivity

One in eight U.S. women will develop invasive breast cancer over her lifetime, with approximately 282,000 new breast cancer patients and 3.8 million breast cancer survivors in 2021. HER2/neu (human epidermal growth factor receptor 2) protein is a cell surface receptor protein that is expressed in a variety of common cancers, including in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels.

On February 1, 2022 Immix Biopharma, Inc. (Nasdaq: IMMX) ("ImmixBio" or the "Company"), a biopharmaceutical company pioneering Tissue Specific Therapeutics (TSTx) targeting oncology and immuno-dysregulated diseases, reported that management has answered top-voted questions submitted by verified IMMX shareholders at the IMMX Investors Day Event on February 1, 2022 at 9:30am ET (Press release, Immix Biopharma, FEB 1, 2022, View Source [SID1234607575]). ImmixBio welcomed verified shareholders to submit and upvote questions to management from January 6 through January 20, 2022. Answers to top-voted investor questions are viewable at www.immixbio.com/Feb2022QA .

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Investors are an integral part of our community at ImmixBio," said Ilya Rachman, MD PhD, CEO of ImmixBio. "Today we addressed questions upvoted by our investors, and are looking forward to an ongoing dialogue through our Q&A platform open to all IMMX shareholders."